Shanghai Universal Biotech Co

Shanghai Universal Biotech Co EBIT

The EBIT of Shanghai Universal Biotech Co (301166.SZ) as of Oct 30, 2026 is -41.95 M CNY. In the previous year, EBIT was -25.53 M CNY — a change of 64.32% (lower).

EBIT

-41.95 MCNY

YoY

64.32%

Last updated:

In 2025, Shanghai Universal Biotech Co's EBIT was -41.95 M CNY, a 64.32% increase from the -25.53 M CNY EBIT recorded in the previous year.

The Shanghai Universal Biotech Co EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT
Date
EBIT
Jan 1, 2018
51.30 M CNY
Jan 1, 2019
79.94 M CNY
Jan 1, 2020
96.15 M CNY
Jan 1, 2021
138.09 M CNY
Jan 1, 2022
105.03 M CNY
Jan 1, 2023
15.35 M CNY
Jan 1, 2024
-25.53 M CNY
Jan 1, 2025
-41.95 M CNY
The Shanghai Universal Biotech Co EBIT history
YEAREBITYoY
-41.95 MCNY+64.32%
-25.53 MCNY-266.32%
15.35 MCNY-85.39%
105.03 MCNY-23.94%
138.09 MCNY+43.62%
96.15 MCNY+20.27%
79.94 MCNY+55.85%
51.30 MCNY+415.52%
9.95 MCNY+1,022.05%
886,800.00CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shanghai Universal Biotech Co Revenue

Shanghai Universal Biotech Co Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
603.99 M CNY
51.30 M CNY
39.87 M CNY
Jan 1, 2019
786.93 M CNY
79.94 M CNY
57.94 M CNY
Jan 1, 2020
849.08 M CNY
96.15 M CNY
76.49 M CNY
Jan 1, 2021
1.11 B CNY
138.09 M CNY
108.73 M CNY
Jan 1, 2022
1.20 B CNY
105.03 M CNY
106.60 M CNY
Jan 1, 2023
1.23 B CNY
15.35 M CNY
40.32 M CNY
Jan 1, 2024
1.12 B CNY
-25.53 M CNY
10.15 M CNY
Jan 1, 2025
1.08 B CNY
-41.95 M CNY
-22.95 M CNY

Shanghai Universal Biotech Co Margins

Shanghai Universal Biotech Co stock margins

The Shanghai Universal Biotech Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Shanghai Universal Biotech Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Shanghai Universal Biotech Co.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
21.33 %
8.49 %
6.60 %
Jan 1, 2019
22.27 %
10.16 %
7.36 %
Jan 1, 2020
22.77 %
11.32 %
9.01 %
Jan 1, 2021
23.19 %
12.44 %
9.80 %
Jan 1, 2022
22.31 %
8.79 %
8.92 %
Jan 1, 2023
19.62 %
1.25 %
3.29 %
Jan 1, 2024
18.06 %
-2.28 %
0.91 %
Jan 1, 2025
18.79 %
-3.87 %
-2.12 %

Shanghai Universal Biotech Co Stock analysis

What does Shanghai Universal Biotech Co do? Shanghai Universal Biotech Co., Ltd. generates revenue through the provision of life science research services, including the supply of third-party brand life science instruments and consumables, alongside its own independent brand products. The company's life science reagents, such as immunological reagents based on antibodies and antibody-related reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, are primarily sourced from third-party brands with supplementary independent brand offerings. Clients purchasing these products include research institutions and laboratories requiring comprehensive technical services like experimental services and technical support. The company focuses on life science instruments and consumables, covering detection, analysis, and sample preparation, while its comprehensive technical services support the operational needs of its clients. The business model emphasizes third-party brand products as the main supply, with independent brand products serving as a supplement. This approach allows Shanghai Universal Biotech to offer a diverse range of life science reagents and instruments without the need for extensive in-house manufacturing. The company's client base primarily consists of entities within the life science research sector seeking reliable reagents, instruments, and technical support to advance their scientific work. By leveraging third-party brands for core products and developing its own independent brand for supplementary offerings, the company optimizes its product portfolio to meet market demands effectively. Shanghai Universal Biotech's revenue streams are derived from the sale of life science reagents, instruments, and consumables, alongside comprehensive technical services. The life science reagents category includes immunological reagents, molecular biology reagents, cell biology reagents, and biochemical reagents, all of which are supplied through a mix of third-party and independent brands. Instruments and consumables focus on detection, analysis, and sample preparation, catering to the technical needs of research institutions. The comprehensive technical services, such as experimental services and technical support, further enhance the value proposition for clients requiring end-to-end solutions in life science research. Shanghai Universal Biotech Co is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Shanghai Universal Biotech Co's EBIT

Shanghai Universal Biotech Co's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Shanghai Universal Biotech Co's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Shanghai Universal Biotech Co's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Shanghai Universal Biotech Co’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Shanghai Universal Biotech Co stock

EBIT of Shanghai Universal Biotech Co is -41.95 M CNY in 2025.

EBIT of Shanghai Universal Biotech Co changed from -25.53 M CNY to -41.95 M CNY, representing a 64.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Shanghai Universal Biotech Co since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Shanghai Universal Biotech Co historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Shanghai Universal Biotech Co

All Key Metrics — Shanghai Universal Biotech Co